SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
April 16, 2003
Date of Report (Date of earliest event reported)
---------------
VIROLOGIC, INC.
(Exact name of Registrant as specified in charter)
Delaware 000-30369 94-3234479
(State or other jurisdiction (Commission File (I.R.S. Employer
of incorporation) Number) Identification No.)
---------------
345 Oyster Point Blvd.
South San Francisco, California 94080
(650) 635-1100
(Address, including zip code, and telephone number,
including area code, of principal executive officers)
---------------
N/A
(Former name or former address, if changed since last report)
---------------
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE
On April 14, 2003, ViroLogic, Inc. (the "Company") received written confirmation
from the Nasdaq Stock Market, Inc. ("Nasdaq") that the Company was in compliance
with the minimum stockholders' equity and minimum bid price requirements for
continued listing on The Nasdaq National Market.
In a preliminary Proxy Statement recently filed with the U.S. Securities and
Exchange Commission for the Company's upcoming 2003 Annual Meeting of
Stockholders, the Company included a draft proposal that sought to provide its
Board of Directors with discretionary authority to decide whether to implement
one of a series of alternative reverse stock splits. In light of the
confirmation that the Company is in compliance with Nasdaq's minimum bid price
requirement, the Company has determined to not submit this proposal at its 2003
Annual Meeting.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VIROLOGIC, INC.
Dated: April 16, 2003 By: /s/ KATHY HIBBS
---------------------------
Kathy Hibbs
Vice President and General Counsel
3